G protein-coupled receptor
CB1 receptor
Cannabinoid receptor 1
- GeneCNR1
- FamilyCannabinoid & related receptors
- GroupCannabinoid receptors
The CB1 receptor is a G protein-coupled receptor for cannabinoids. The human receptor was cloned from brain stem tissue and is 97 percent identical to the rat receptor. Its messenger RNA is abundant in the brain and present at lower levels in the testis.1 A review of the endocannabinoid system describes CB1 and CB2 as the two G protein-coupled receptors that mediate many of the effects of cannabinoids. CB1 receptors are present at very high levels in several brain regions and in lower amounts in a more widespread fashion, and they mediate many of the psychoactive effects of cannabinoids. Both receptors couple primarily to inhibitory G proteins.2 THC and the synthetic agonist CP 55,940 bind CB1 and CB2 about equally well. CB1 inhibits the formation of cyclic AMP, and in addition it inhibits Q-type calcium channels and opens inwardly rectifying potassium channels.3
In the brains of several mammals, humans included, it is densest in the outflow nuclei of the basal ganglia (substantia nigra pars reticulata and globus pallidus), in the hippocampus and in the cerebellum. It is sparse in the lower brainstem areas that control breathing and the heart, which may explain why high doses of THC are not lethal.4 Autoradiography showed that CB1 receptors are expressed at high levels in the brain regions expected from the psychoactive effects of THC, and at low levels in regions unaffected by cannabinoids, such as the respiratory centres of the medulla. They are expressed more abundantly than most other G protein-coupled receptors, and combined with in situ hybridisation the work suggested that they might be concentrated on axon terminals.2 The brain makes a substance that binds the receptor: anandamide (arachidonylethanolamide) was isolated from pig brain, and in a mouse tissue test it acted like the psychotropic cannabinoids.5
Mice without CB1 do not respond to cannabinoids, with no pain relief, reward, fall in body temperature, slowed movement or fall in blood pressure. In them morphine is also less rewarding, and withdrawal from it is milder.6 In another knockout strain, the mice appeared healthy and fertile, but had a significantly increased mortality rate. They showed reduced locomotor activity, increased ring catalepsy and hypoalgesia in the hotplate and formalin tests. THC-induced ring catalepsy, hypomobility and hypothermia were completely absent, while THC-induced analgesia in the tail-flick test and some other responses, among them diarrhoea, were still seen. The authors conclude that most, but not all, central nervous system effects of THC are mediated by the CB1 receptor.7 In 63 healthy men who smoked cannabis, the CB1 blocker rimonabant (SR141716) reduced the high and the rise in heart rate in a dose-dependent way, without changing THC levels in the blood.8
Rimonabant, a CB1 blocker, was approved as a weight-loss drug. A meta-analysis of four double-blind trials with 4,105 participants found that 20 mg a day gave a 4.7 kg greater weight reduction after one year than placebo. It also caused significantly more adverse events and 1.4 times more serious adverse events. Patients given rimonabant were 2.5 times more likely to stop treatment because of depressive mood disorders and 3.0 times more likely to stop because of anxiety, although depressed mood was an exclusion criterion in the trials.9
A review of the adverse health effects of recreational marijuana use states that long-term use can lead to addiction. About 9 percent of those who experiment with marijuana become addicted, about 1 in 6 of those who start as teenagers, and 25 to 50 percent of those who smoke daily. Regular use is also associated with anxiety and depression, but causality has not been established. Marijuana is linked with psychosis, especially in people with a genetic vulnerability, and heavier use, higher potency and an earlier start can bring forward a first psychotic episode by 2 to 6 years, although it is difficult to establish causality in these studies.10
Cannabidiol acts on CB1 as a negative allosteric modulator: in cells it reduced the efficacy and potency of THC and of the endocannabinoid 2-AG.11
Sources (11)
- Gérard et al. 1991Gérard CM, Mollereau C, Vassart G, et al. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem J
- Mackie 2008Mackie K (2008) Cannabinoid receptors: where they are and what they do J Neuroendocrinol
- Felder et al. 1995Felder CC, Joyce KE, Briley EM, et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol Pharmacol
- Herkenham et al. 1990Herkenham M, Lynn AB, Little MD, et al. (1990) Cannabinoid receptor localization in brain Proc Natl Acad Sci U S A
- Devane et al. 1992Devane WA, Hanus L, Breuer A, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science
- Ledent et al. 1999Ledent C, Valverde O, Cossu G, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science
- Zimmer et al. 1999Zimmer A, Zimmer AM, Hohmann AG, et al. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci U S A
- Huestis et al. 2001Huestis MA, Gorelick DA, Heishman SJ, et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch Gen Psychiatry
- Christensen et al. 2007Christensen R, Kristensen PK, Bartels EM, et al. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet
- Volkow et al. 2014Volkow ND, Baler RD, Compton WM, et al. (2014) Adverse health effects of marijuana use N Engl J Med
- Laprairie et al. 2015Laprairie RB, Bagher AM, Kelly ME, et al. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor Br J Pharmacol
Binding affinity (Kᵢ)
10 substances, 24 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.
Human
9 measurements
HU-2101.7 nMGovaerts SophieJ et al. 2004 · 3 reports
- Assay
- CHO cells expressing human CB1, [3H]CP 55,940 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 0.06–1.7 nM in 3 reports
Values depend on the assay, species or conditions, and each is valid only for its own. 3 reports in all, 0.06–1.7 nM.
Sources and values behind the range, same assay family Report Value Where Govaerts SophieJ et al. 2004 1.7 nM Table 2 Felder et al. 1995 0.06 nM Table 1 Felder et al. 1992 0.06 nM Table 1 Nabilone2.2 nMGareau et al. 1996 · 2 reports
- Assay
- Human CB1 receptor; [3H](-)CP-55940 displacement (cell system not stated)
- Shown value from
- Gareau et al. 1996, Table 3 (compound 8)
- Range
- 2.2–79 nM in 2 reports
- Error
- ± 0.89 SEM
Sources and values behind the range, same assay family Report Value Where Gareau et al. 1996 2.2 nM Table 3 (compound 8) Felder et al. 1992 79 nM Table 1 CP 55,9406.6 nMGovaerts SophieJ et al. 2004 · 6 reports
- Assay
- CHO cells expressing human CB1, [3H]CP 55,940 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 1.0–13 nM in 6 reports
Reported values disagree and no value is established. 6 reports in all, 1.0–13 nM.
Sources and values behind the range, same assay family Report Value Where Zagzoog et al. 2020 13 nM Table 1 Scott et al. 2019 1.0 nM Table 1 Govaerts SophieJ et al. 2004 6.6 nM Table 2 Felder et al. 1995 3.7 nM Table 1 Felder et al. 1992 3.7 nM Table 1 Ross et al. 1999 5.0 nM Table 1 Δ⁹-THC (Tetrahydrocannabinol)20 nMWiley et al. 2024 · 6 reports
- Assay
- HEK293 membranes expressing human CB1; [3H]CP55,940 competition binding
- Shown value from
- Wiley et al. 2024, Table 1
- Range
- 18–53 nM in 6 reports
This is the best-supported value. Other reports differ. 10 reports in all, 10–128 nM.
Sources and values behind the range, same assay family Report Value Where Wiley et al. 2024 20 nM Table 1 Husni et al. 2014 18 nM Table 1 Zagzoog et al. 2020 36 nM Table 1 Govaerts SophieJ et al. 2004 32 nM Table 2 Felder et al. 1995 53 nM Table 1 Felder et al. 1992 53 nM Table 1 Δ⁸-THC (Tetrahydrocannabinol)36 nMWiley et al. 2024 · 3 reports
- Assay
- HEK293 membranes expressing human CB1; [3H]CP55,940 competition binding
- Shown value from
- Wiley et al. 2024, Table 1
- Range
- 36–251 nM in 3 reports
This is the best-supported value. Other reports differ. 3 reports in all, 36–251 nM.
Sources and values behind the range, same assay family Report Value Where Wiley et al. 2024 36 nM Table 1 Husni et al. 2014 78 nM Table 1 Govaerts SophieJ et al. 2004 251 nM Table 2 WIN 55,212-2129 nMGovaerts SophieJ et al. 2004 · 5 reports
- Assay
- CHO cells expressing human CB1, [3H]CP 55,940 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 8.1–564 nM in 5 reports
Sources and values behind the range, same assay family Report Value Where Govaerts SophieJ et al. 2004 129 nM Table 2 Felder et al. 1995 62 nM Table 1 Felder et al. 1992 564 nM Table 1 Navarro et al. 2020 8.1 nM, 9.9 nM Table 1 Cannabinol (CBN)285 nMWiley et al. 2024 · 3 reports
- Assay
- HEK293 membranes expressing human CB1; [3H]CP55,940 competition binding
- Shown value from
- Wiley et al. 2024, Table 1
- Range
- 75–1130 nM in 3 reports
This is the best-supported value. Other reports differ. 3 reports in all, 75–1130 nM.
Sources and values behind the range, same assay family Report Value Where Wiley et al. 2024 285 nM Table 1 Husni et al. 2014 75 nM Table 1 Felder et al. 1995 1130 nM Table 1 Cannabigerol (CBG)1300 nMZagzoog et al. 2020 · 3 reports
- Assay
- CHO membranes stably expressing human receptor; [3H]CP55,940 displacement; variable-slope four-parameter fit; independent experiments in duplicate
- Shown value from
- Zagzoog et al. 2020, Table 1
- Range
- 1045–3090 nM in 3 reports
Sources and values behind the range, same assay family Report Value Where Husni et al. 2014 3090 nM Table 1 Zagzoog et al. 2020 1300 nM Table 1 Navarro et al. 2020 1045 nM Table 1 Cannabidiol (CBD)4330 nMWiley et al. 2024 · 4 reports
- Assay
- HEK293 membranes expressing human CB1; [3H]CP55,940 competition binding
- Shown value from
- Wiley et al. 2024, Table 1
- Range
- 151–4330 nM in 4 reports
This is the best-supported value. Other reports differ. 11 reports in all, 151–4330 nM.
Sources and values behind the range, same assay family Report Value Where Wiley et al. 2024 4330 nM Table 1 Husni et al. 2014 151 nM Table 1 Zagzoog et al. 2020 200 nM Table 1 Navarro et al. 2020 1690 nM Table 1
Mouse
8 measurements
CP 55,9400.30 nMGovaerts SophieJ et al. 2004
- Assay
- mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
HU-2100.32 nMGovaerts SophieJ et al. 2004
- Assay
- mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
JWH-0181.2 nMBrents et al. 2011
- Assay
- mouse whole-brain membrane homogenate containing CB1 receptors; [3H]CP-55,940 competition binding
- Shown value from
- Brents et al. 2011, Figure 2 and Results
WIN 55,212-27.1 nMGovaerts SophieJ et al. 2004
- Assay
- mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
Δ⁹-THC (Tetrahydrocannabinol)15 nMBrents et al. 2011 · 2 reports
- Assay
- mouse whole-brain membrane homogenate containing CB1 receptors; [3H]CP-55,940 competition binding
- Shown value from
- Brents et al. 2011, Figure 2 and Results
- Range
- 15–98 nM in 2 reports
This is the best-supported value. Other reports differ. 3 reports in all, 15–98 nM.
Sources and values behind the range, same assay family Report Value Where Brents et al. 2011 15 nM Figure 2 and Results Govaerts SophieJ et al. 2004 98 nM Table 2 Δ⁸-THC (Tetrahydrocannabinol)123 nMGovaerts SophieJ et al. 2004
- Assay
- mouse cerebellum membranes, [3H]WIN 55,212-2 displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
Cannabidiol (CBD)259 nMLaprairie et al. 2015 · 3 reports
- Assay
- STHdhQ7/Q7 mouse striatal cells; operational model of allosterism, PLCβ3 phosphorylation, THC as orthosteric probe
- Shown value from
- Laprairie et al. 2015, Table 5
- Range
- 259–329 nM in 3 reports
Cannabigerol (CBG)381 nMCascio et al. 2010
- Assay
- MF1 mouse whole-brain membranes; displacement of [3H]CP55940
- Shown value from
- Cascio et al. 2010, Figure 6 legend
This is the best-supported value. Other reports differ. 3 reports in all, 33–381 nM.
Rat
6 measurements
HU-2100.23 nMHowlett et al. 1990 · 5 reports
- Assay
- Rat brain cortex membranes; [3H]CP-55,940 displacement
- Shown value from
- Howlett et al. 1990, Results, Fig. 4
- Range
- 0.10–2.8 nM in 5 reports
- Error
- ± 0.03 SEM
Values depend on the assay, species or conditions, and each is valid only for its own. 5 reports in all, 0.10–2.8 nM.
Sources and values behind the range, same assay family Report Value Where Howlett et al. 1990 0.23 nM Results, Fig. 4 Govaerts SophieJ et al. 2004 2.8 nM Table 2 Rhee et al. 1997 0.19 nM, 0.10 nM Table 1 Griffin et al. 1998 0.73 nM Table 2, column CB1 Ki JWH-0189.0 nMAung et al. 2000
- Assay
- rat cerebral cortex P2 membrane homogenate; [3H]CP-55,940 competition binding
- Shown value from
- Aung et al. 2000, Table 1
CP 55,94038 nMGovaerts SophieJ et al. 2004 · 2 reports
- Assay
- rat cerebellum membranes, [3H]SR 141716A displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 0.58–38 nM in 2 reports
Sources and values behind the range, same assay family Report Value Where Govaerts SophieJ et al. 2004 38 nM Table 2 Griffin et al. 1998 0.58 nM Table 2, column CB1 Ki Δ⁹-THC (Tetrahydrocannabinol)209 nMGovaerts SophieJ et al. 2004 · 4 reports
- Assay
- rat cerebellum membranes, [3H]SR 141716A displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 41–209 nM in 4 reports
Values depend on the assay, species or conditions, and each is valid only for its own. 4 reports in all, 41–209 nM.
Sources and values behind the range, same assay family Report Value Where Govaerts SophieJ et al. 2004 209 nM Table 2 Rhee et al. 1997 67 nM, 80 nM Table 1 Griffin et al. 1998 41 nM Table 2, column CB1 Ki Cannabinol (CBN)211 nMRhee et al. 1997 · 3 reports
- Assay
- COS-7 cells transfected with rat CB1 cDNA, displacement of [3H]HU-243
- Shown value from
- Rhee et al. 1997, Table 1
- Range
- 211–392 nM in 3 reports
Sources and values behind the range, same assay family Report Value Where Rhee et al. 1997 392 nM, 211 nM Table 1 Griffin et al. 1998 308 nM Table 2, column CB1 Ki WIN 55,212-2282 nMGovaerts SophieJ et al. 2004 · 2 reports
- Assay
- rat cerebellum membranes, [3H]SR 141716A displacement
- Shown value from
- Govaerts SophieJ et al. 2004, Table 2
- Range
- 1.9–282 nM in 2 reports
Sources and values behind the range, same assay family Report Value Where Govaerts SophieJ et al. 2004 282 nM Table 2 Griffin et al. 1998 1.9 nM Table 2, column CB1 Ki
Unspecified
1 measurement
JWH-0189.0 nMBanister et al. 2015
- Assay
- literature binding value as compiled in Table S8, original assay of Aung 2000 (Drug Alcohol Depend 60:133)
- Shown value from
- Banister et al. 2015, Table S8 (Supporting Information)
Functional potency (EC₅₀)
9 substances, 17 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
9 measurements
HU-2100.20 nMRyberg et al. 2007
- Assay
- HEK293 membranes expressing human CB1, [35S]GTPgammaS binding
- Shown value from
- Ryberg et al. 2007, Table 1
- Error
- ± 0.03 SEM, n = 5
- Emax
- 91.0 ± 2.0%
CP 55,9407.7 nMZagzoog et al. 2020 · 2 reports
- Assay
- HitHunter CHO cells stably expressing human receptor; inhibition of forskolin-stimulated cAMP for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
- Shown value from
- Zagzoog et al. 2020, Table 2
- Range
- 2.6–7.7 nM in 2 reports
- Emax
- 100.0 ± 6.2%
Values depend on the assay, species or conditions, and each is valid only for its own. 5 reports in all, 0.20–920 nM.
Sources and values behind the range, same assay family Report Value Where Zagzoog et al. 2020 7.7 nM Table 2 Ross et al. 1999 2.6 nM Table 2 WIN 55,212-218 nMRyberg et al. 2007
- Assay
- HEK293 membranes expressing human CB1, [35S]GTPgammaS binding
- Shown value from
- Ryberg et al. 2007, Table 1
- Error
- ± 3.0 SEM, n = 5
- Emax
- 101.0 ± 14.0%
JWH-018102 nMBanister et al. 2015
- Assay
- mouse AtT-20 cells stably expressing human CB1, FLIPR membrane-potential/GIRK assay
- Shown value from
- Banister et al. 2015, Table 1
- Emax
- 107.0 ± 6.0%
Reported values disagree and no value is established. 2 reports in all, 23–102 nM.
Cannabigerol (CBG)120 nMZagzoog et al. 2020
- Assay
- HitHunter CHO cells stably expressing human receptor; inhibition of forskolin-stimulated cAMP for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
- Shown value from
- Zagzoog et al. 2020, Table 2
- Emax
- 68.0 ± 2.4%
Δ⁹-THC (Tetrahydrocannabinol)250 nMBanister et al. 2015
- Assay
- mouse AtT-20 cells stably expressing human CB1, FLIPR membrane-potential/GIRK assay
- Shown value from
- Banister et al. 2015, Table 1
- Emax
- 51.0 ± 3.0%
This is the best-supported value. Other reports differ. 8 reports in all, 6.0–470 nM.
Cannabinol (CBN)307 nMHusni et al. 2014
- Assay
- HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
- Shown value from
- Husni et al. 2014, Table 1
Cannabidiol (CBD)1469 nMHusni et al. 2014
- Assay
- HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
- Shown value from
- Husni et al. 2014, Table 1
Δ⁸-THC (Tetrahydrocannabinol)5820 nMHusni et al. 2014
- Assay
- HEK293 cells expressing human CB1 membranes; [35S]GTPγS functional assay
- Shown value from
- Husni et al. 2014, Table 1
Mouse
2 measurements
JWH-0186.8 nMBrents et al. 2011
- Assay
- mouse whole-brain membrane homogenate; [35S]GTPγS functional assay
- Shown value from
- Brents et al. 2011, Figure 3B and Results
Δ⁹-THC (Tetrahydrocannabinol)167 nMBrents et al. 2011
- Assay
- mouse whole-brain membrane homogenate; [35S]GTPγS functional assay
- Shown value from
- Brents et al. 2011, Figure 3B and Results
Rat
3 measurements
HU-2100.55 nMGriffin et al. 1998
- Assay
- rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
- Shown value from
- Griffin et al. 1998, Table 2
- Emax
- 140.0%
CP 55,94018 nMGriffin et al. 1998
- Assay
- rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
- Shown value from
- Griffin et al. 1998, Table 2
- Emax
- 114.0%
WIN 55,212-2151 nMGriffin et al. 1998
- Assay
- rat cerebellar membranes, [35S]GTPγS binding at 100 µM GDP
- Shown value from
- Griffin et al. 1998, Table 2
- Emax
- 156.0%
Unspecified
3 measurements
HU-2100.04 nMRhee et al. 1997
- Assay
- cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
- Shown value from
- Rhee et al. 1997, Table 1
Δ⁹-THC (Tetrahydrocannabinol)11 nMRhee et al. 1997
- Assay
- cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
- Shown value from
- Rhee et al. 1997, Table 1
Cannabinol (CBN)120 nMRhee et al. 1997
- Assay
- cells transfected with CB1, inhibition of forskolin-stimulated adenylyl cyclase
- Shown value from
- Rhee et al. 1997, Table 1
Also reported to act here
Substances reported to act here, without a displayed value.
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.